Ferumoxytol patent extended by USPTO

AMAG Pharmaceuticals, Inc. has had a US patent covering ferumoxytol extended.

Ferumoxytol is an iron preparation administered to patients who suffer blood loss after undertaking kidney dialysis.

Patent ‘498 was granted by the US Patent and Trademarks Office (USPTO) in 2009, and covers a method of heating ferumoxytol to be administered by injections. The patent was due to expire in 2020.

The patent is listed in the Orange Book, a record of drugs approved by the Food and Drug Administration.

The USPTO granted an extension of the patent until June 30, 2023.

William Heiden, chief executive of AMAG, said: “This patent extension for ferumoxytol further lengthens our IP protection and enhances the long-term value of a product that generated 28% revenue growth in the US in 2013 for our company.”